Compare
AEON Biopharma, Inc. vs Jupiter Neurosciences, Inc. vs CDT Equity Inc. vs 60 Degrees Pharmaceuticals, Inc.
| Latest fiscal year | AEON Biopharma, Inc. AEON | Jupiter Neurosciences, Inc. JUNS | CDT Equity Inc. CDT | 60 Degrees Pharmaceuticals, Inc. SXTP |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $21.8K | n/a | $1.01M |
| Revenue growth (YoY) | n/a | n/a | n/a | +65.5% |
| Gross margin | n/a | 80.6% | n/a | 22.3% |
| Operating margin | n/a | n/m | n/a | -771.6% |
| Net margin | n/a | n/m | n/a | -732.5% |
| Net income | -$39.22M | -$8.64M | -$39.22M | -$7.37M |
| EPS (Diluted) | -$3.95 | -$0.25 | -$1177.89 | -$11.73 |
| Operating cash flow | -$17.31M | -$5.41M | -$15.55M | -$6.85M |
| Free cash flow | -$17.31M | n/a | n/a | -$6.99M |
| Cash & equivalents | $3.01M | n/a | $1.51M | $1.51M |
| Total assets | $5.56M | $5.56M | $5.65M | $5.37M |
| Total liabilities | $60.59M | $7.40M | $12.82M | $1.99M |
| Shareholders' equity | -$55.03M | -$1.83M | -$7.17M | $3.46M |
| Return on year-end equity | n/a | n/a | n/a | -212.7% |
| Shares outstanding | 12.11M | 34.45M | 92.1K | 1.16M |
Revenue, most recent five fiscal years
| Fiscal year | AEON Biopharma, Inc. | Jupiter Neurosciences, Inc. | CDT Equity Inc. | 60 Degrees Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | n/a | $21.8K Ended 2025-12-31 | n/a | $1.01M Ended 2025-12-31 |
| 1 year earlier | n/a | $0 Ended 2024-12-31 | n/a | $607.6K Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | n/a | $253.6K Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | $223.2K Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | n/a |